La cadena de opciones muestra datos clave de las opciones de acciones de Edesa Biotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Edesa Biotech..

Edesa Biotech (NASDAQ:EDSA) Bolsa, Cadena de Opciones

Edesa Biotech

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AMOD

DGLY

EDSA

El Índice de Precios al Productor en EE. UU. subió un 3,5% en enero, superando las previsiones. ¿Cómo reaccionaron los mercados?

Acciones de EE. UU. reaccionan al alza tras el aumento del PPI: ¿qué esperar ahora?

Edesa Biotech Inc

Biotech

General

Opus Genetics Announces One-Month Clinical Data From Pediatric Patient in Phase 1/2 Trial; Says First Pediatric Patient Shows Encouraging Early Safety Profile And Meaningful Improvement In Visual Function At One Month

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy and maintains $28 price target.

Price Target

Reiteration

Analyst Ratings

KALV

Needham Reiterates Buy on KalVista Pharma, Maintains $28 Price Target

Citigroup analyst Ariel Rosa upgrades Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) from Sell to Neutral and lowers the price target from $32 to $29.

Upgrades

WERN

Citigroup Upgrades Werner Enterprises to Neutral, Lowers Price Target to $29

Health Care

ADPT

Adaptive Biotechnologies Announces That Palmetto GBA, A Medicare Administrative Contractor Expanded Coverage Of clonoSEQ

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/DAL/earnings">opening bell on Wednesday, April 9</a>.
Analysts expect the company to report quarterly earnings at 39 cents per share, down from 45 cents per share in the year-ago period. Delta Air Lines projects quarterly revenue of $13.46 billion, compared to $13.75 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Monday, UBS analyst Thomas Wadewitz downgraded Delta from Buy to Neutral. He also lowered the price target from $77 to $42. Susquehanna analyst Christopher Stathoulopoulos maintained the stock with a Positive rating and slashed the price target from $80 to $50.
With the recent buzz around Delta Air Lines, some investors may be eyeing potential gains from the company's dividends too. As of now, Delta Air Lines offers an annual dividend yield of 1.61%. That&#8217;s a quarterly dividend amount of 15 cents per share (60 cents a year).
To figure out how to earn $500 monthly from Delta Air Lines, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Delta's $0.60 dividend: $6,000 / $0.60 = 10,000 shares.
So, an investor would need to own approximately $372,900 worth of Delta Air Lines, or 10,000 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.60 = 2,000 shares, or $74,580 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
DAL Price Action: Shares of Delta Air Lines gained by 0.1% to close at $37.29 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a></li>
<li>Image: Shutterstock</li>
</ul>

Long Ideas

How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q1 Earnings

Citigroup analyst Ariel Rosa upgrades Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Neutral to Buy and lowers the price target from $260 to $244.

Citigroup Upgrades Union Pacific to Buy, Lowers Price Target to $244

SCNX

SCIENTURE Announces Divestiture Of Its Legacy Healthcare IT And Wholesale Operations Subsidiaries To Tollo Health

Micron Tells U.S. Customers It Will Impose A Tariff-Related Surcharge On Some Products From April 9, 2025

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL&#x2122;
JOTROL&#x2122; development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure
Jupiter, Florida, April 08, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL&#x2122;, a patented resveratrol-based platform, today announced the release of its first shareholder letter as a publicly traded company. The letter from Chairman and CEO Christer Rosén outlines the Company's 2025 strategic roadmap, including key clinical and commercial milestones designed to create long-term value and establish near-term revenue.
Dear Fellow Shareholders,
It is a distinct pleasure to share our first annual letter to shareholders, following our successful debut on the Nasdaq Capital Market in December 2024 under the symbol JUNS. That significant milestone marked more than just an entry into the public markets — it signaled the beginning of a new era for Jupiter Neurosciences, defined by increased visibility, enhanced resources, and a bold vision for advancing transformative therapies in neuroscience and longevity.
Building Momentum
With our Nasdaq listing in place, we are now focused on advancing our lead clinical asset, JOTROL&#x2122;, into a Phase 2a clinical trial in Parkinson's disease, expanding our presence in Asia, and launching a new consumer-facing longevity initiative. Becoming a publicly traded company has amplified awareness of our mission — to pioneer treatments that target the underlying causes of neuroinflammation and mitochondria in both rare and widespread neurological disorders. By entering the rapidly growing Longevity and Healthspan market, we are leveraging years of preclinical and clinical development with JOTROL&#x2122; to establish a scientifically grounded, near-term revenue-generating business alongside our therapeutic pipeline.
JOTROL&#x2122;: Unlocking Resveratrol's Untapped Potential
At the core of our pipeline is JOTROL&#x2122;, an enhanced resveratrol formulation developed in partnership with Aquanova AG. Leveraging proprietary micellar technology, JOTROL&#x2122; resolves long-standing bioavailability and gastrointestinal tolerability issues that have hindered therapeutic resveratrol applications for decades. Our Phase 1 study demonstrated more than nine-fold improved bioavailability versus standard resveratrol, and this data now serves as the regulatory foundation across all upcoming clinical trials.
With its ability to cross the blood-brain barrier and modulate key inflammatory pathways such as NLRP3, JOTROL&#x2122; is uniquely positioned as a novel therapeutic platform for neurodegenerative diseases, including Parkinson's disease (JNS115) and Mild Cognitive Impairment/Early Alzheimer's (JNS108). The additional benefit of JOTROL&#x2122; increasing mitochondrial structure and function is a compounding mechanism that is core to our therapeutic strategy, with treatment benefit in neurodegenerative disease and cancer. Our upcoming Parkinson's trial, in collaboration with Zina Biopharmaceuticals and Catalent, is on track to begin dosing in Q3 2025.

JUNS

Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter Including Lead Clinical Asset, Jotrol Into A Phase 2A Clinical Trial In Parkinson's Disease

Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and maintains $15 price target.

OCUL

Needham Reiterates Buy on Ocular Therapeutix, Maintains $15 Price Target

AMTX

Aemetis Production Of Renewable Natural Gas Increased 55% In Mar.

Management

NNDM

Nano Dimension Appoints Ofir Baharav As CEO

Citigroup analyst Ariel Rosa upgrades Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) from Sell to Neutral and lowers the price target from $25 to $23.

SNDR

Citigroup Upgrades Schneider National to Neutral, Lowers Price Target to $23

<ul>
<li>Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1</li>
<li>Long-term seizure reduction with a median reduction of 82% at 3 years.</li>
<li>Seizure freedom with 42% of patients remaining seizure free for 6+ months.i</li>
</ul>

NPCE

NeuroPace Presented Data From Long-Term Post-Approval Study Of RNS System On Apr. 7; Says Long-Term Seizure Reduction With A Median Reduction Of 82% At 3 Years

Citigroup analyst Ariel Rosa upgrades Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) from Neutral to Buy and lowers the price target from $186 to $183.

ODFL

Citigroup Upgrades Old Dominion Freight Line to Buy, Lowers Price Target to $183

<h3>Gainers</h3>
<ul>
<li>Unifi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) stock moved upwards by 34.3% to $5.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $109.9 million. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) stock rose 28.1% to $1.14. The market value of their outstanding shares is at $1.7 million. </li>
<li>MarineMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) shares moved upwards by 24.45% to $23.0. The company's market cap stands at $522.2 million. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares increased by 22.42% to $0.81. The company's market cap stands at $6.9 million. </li>
<li>El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) shares increased by 14.22% to $10.6. The company's market cap stands at $315.6 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) stock rose 13.79% to $4.95. The company's market cap stands at $253.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares decreased by 28.6% to $1.6 during Tuesday's pre-market session. The company's market cap stands at $3.5 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock decreased by 16.32% to $0.33. The company's market cap stands at $93.3 million. </li>
<li>United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) stock declined by 15.76% to $2.3. The market value of their outstanding shares is at $134.7 million. </li>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) stock decreased by 15.49% to $0.44. The market value of their outstanding shares is at $8.1 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock decreased by 14.25% to $0.05. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares fell 13.3% to $0.35. The company's market cap stands at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

LOBO

LOCO

MKDW

MULN

NWTN

TRNR

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

Panama&#8217;s chief auditor expressed grave concerns over the proposed acquisition of two crucial Panama Canal ports by BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>).
What Happened: The Hong Kong-based company, CK Hutchison, is suspected of being in debt for hundreds of millions in unpaid fees and did not secure the necessary clearances for the ports. This could potentially disrupt BlackRock&#8217;s plans to acquire&nbsp;the ports as part of&nbsp;a $22.8 billion deal.
Panama's Comptroller General, Anel Flores, accused Panama Ports, operated by Hutchison, of extending its 2021 contract with the Panama Maritime Authority without required clearances. He also stated the company used tax-exempt subcontractors to lower payments to the government and failed to share 10% of its profits as obligated, <a href="https://www.scmp.com/news/hong-kong/politics/article/3305584/hong-kongs-ck-hutchison-did-not-uphold-panama-canal-ports-contract-panama-audit">reported</a> the South China Morning Post.
Panama's comptroller general accused CK Hutchison of depriving the country of over $1.3 billion through a decades-old port concession that was &#8220;negotiated against the Republic.&#8221; Flores plans to file criminal charges and inform the Panama Maritime Authority, which may consider revoking the concessions. 
The acquisition has become a point of tension between the U.S. and China amid an escalating trade war. Last month, a consortium led by BlackRock revealed the port deal with Hutchison's founder, Li Ka-shing, shortly after President Donald Trump accused China of exerting excessive control over the Panama Canal.
However, the deal has encountered pushback from Beijing, with state-affiliated media portraying it as a betrayal of the Chinese public. China&#8217;s antitrust officials have announced a review of the acquisition, and alternative buyers are being sought if the deal does not materialize.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44664638/millionaire-crypto-trader-reacts-to-bitcoin-mega-crash-you-have-only-one-job-here-survive" target="_blank" rel="noreferrer noopener">Millionaire Crypto Trader Reacts To Bitcoin Mega-Crash: &#8216;You Have Only One Job Here: Survive&#8217;</a>
Why It Matters: BlackRock&#8217;s CEO, Larry Fink, acknowledged on Monday that the escalating U.S.-China tariff rift could complicate the deal. He added that the ports in question account for about 4% of the total value of a deal that will grant the U.S. firm access to 43 ports across 23 countries. The entire deal will be reviewed as a single transaction. According to Fink, the regulatory review of the deal could take up to nine additional months.
Following the announcement of the port deal,&nbsp;Beijing ordered <a href="https://www.benzinga.com/markets/asia/25/03/44509795/blackrocks-19-biliion-port-deal-with-li-ka-shing-sparks-china-scrutiny-state-firms-told-to-pause-new-ties-report">state-owned companies</a> to halt new partnerships&nbsp;with companies associated with Li Ka-shing, Hutchison&#8217;s founder. This move signaled China&#8217;s scrutiny of the Hong Kong tycoon&#8217;s global business empire.
While Panama claimed its investigation was launched independently to safeguard its financial interests, a source told SCMP that pressure from Trump&#8217;s administration also influenced the government&#8217;s decision.
The deal also coincided with escalating trade tensions&nbsp;between the U.S. and China.&nbsp;<a href="https://www.benzinga.com/markets/25/04/44677506/china-resolutely-opposes-trumps-50-tariff-threat-vows-countermeasures-as-trade-tensions-jolt-markets">China&#8217;s Commerce Ministry &#8220;resolutely opposed&#8221;</a>&nbsp;U.S. President Donald Trump&#8217;s threat to impose additional 50% duties on Chinese imports and vowed to take countermeasures to protect its interests.
<ul>
<li>READ MORE: <a href="https://benzinga.com/news/25/04/44673195/you-have-defeated-the-wealthiest-person-on-earth-says-bernie-sanders-as-he-applauds-wisconsins-choice-of-sus" target="_blank" rel="noreferrer noopener">&#8216;You Have Defeated The Wealthiest Person On Earth,&#8217; Says Bernie Sanders As He Applauds Wisconsin&#8217;s Choice Of Susan Crawford</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BlackRock's $22.8 Billion Panama Canal Port Deal To Hit A Roadblock Amid Audit Findings And Escalating US-China Trade War

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 190.8% to $8.55 during Tuesday's pre-market session. The company's market cap stands at $6.4 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 32.42% to $0.58. The market value of their outstanding shares is at $2.6 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock rose 32.33% to $2.38. The company's market cap stands at $3.5 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 27.36% to $2.67. The company's market cap stands at $13.1 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock increased by 22.32% to $3.89. The company's market cap stands at $8.6 million. </li>
<li>Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) shares increased by 20.07% to $27.51. The market value of their outstanding shares is at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 51.2% to $3.66 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) stock decreased by 46.37% to $1.4. The market value of their outstanding shares is at $109.6 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock declined by 30.25% to $8.05. The company's market cap stands at $209.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 19.02% to $0.7. The company's market cap stands at $8.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 16.44% to $0.27. The company's market cap stands at $2.0 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock decreased by 16.17% to $1.09. The market value of their outstanding shares is at $52.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

CVRX

MYNZ

NAOV

NAYA

PCRX

PHLT

PTIX

STTK

SXTP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

CPRX

Catalyst Pharmaceuticals Announces Health Canada Acceptance Of AGAMREE New Drug Submission With Priority Review For Sub-Licensee Kye Pharmaceuticals

Citigroup analyst Ariel Rosa upgrades Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) from Neutral to Buy and lowers the price target from $53 to $48.

Citigroup Upgrades Knight-Swift to Buy, Lowers Price Target to $48

Events

Press Releases

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Edesa Biotech Announces Upcoming Conference Schedule

Financing

Edesa Biotech's Founder Makes Strategic Investment in the Company

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces Chief Financial Officer Transition

HC Wainwright & Co.

Brookline Capital

Comments

Edesa Biotech

Edesa Biotech (EDSA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL